CASI announced on 17 April 2019 that it had in-licensed the novel CD38 monoclonal antibody TSK011010 from Black Belt Therapeutics. The deal includes a €7m upfront (€5m cash and €2m equity investment) and undisclosed milestones and royalties. The drug is in the pre-IND stage but CASI noted that the IND-enabling studies are complete and it expects to submit IND/IMPD applications at the end of 2019 or early 2020.
26 Apr 2019
CASI Pharmaceuticals - CASI acquires an early stage CD38 mAb
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CASI Pharmaceuticals - CASI acquires an early stage CD38 mAb
CASI Pharmaceuticals, Inc. (CASI:NAS) | 0 0 0.0%
- Published:
26 Apr 2019 -
Author:
Dr Nathaniel Calloway -
Pages:
5
CASI announced on 17 April 2019 that it had in-licensed the novel CD38 monoclonal antibody TSK011010 from Black Belt Therapeutics. The deal includes a €7m upfront (€5m cash and €2m equity investment) and undisclosed milestones and royalties. The drug is in the pre-IND stage but CASI noted that the IND-enabling studies are complete and it expects to submit IND/IMPD applications at the end of 2019 or early 2020.